Open Access

The Epstein-Barr virus latent membrane protein-1 (LMP1) 30-bp deletion and XhoI-polymorphism in nasopharyngeal carcinoma: a meta-analysis of observational studies

Systematic Reviews20154:46

DOI: 10.1186/s13643-015-0037-z

Received: 3 March 2015

Accepted: 26 March 2015

Published: 13 April 2015

Abstract

Background

Epstein-Barr virus (EBV) is considered to be closely associated with nasopharyngeal carcinoma (NPC), in which EBV-encoded latent membrane protein 1 (LMP1) was found to have an oncogenic role. However, the results published on the LMP1 polymorphism are inconsistent. In the present study, we performed a meta-analysis to determine the frequency of the associations and a more precise association between NPC and EBV LMP1 gene variants (30-bp deletion (del)/XhoI-loss).

Methods

Eligible articles met the inclusion/exclusion criteria and were identified in the following electronic databases: PubMed, ScienceDirect, and SciELO. Consequently, the data of interest were extracted and plotted in a table to calculate the frequency and odds ratio (OR) of the outcomes of interest (30-bp del-LMP1/XhoI-loss) in patients with NPC. Study quality (Newcastle-Ottawa Scale (NOS)), publication bias, and heterogeneity were assessed.

Results

Thirty-one observational studies were included with a total of 2,846 individuals (NPC, n = 1,855; control, n = 991). The risk of bias in relation to study quality evaluated by NOS was considered low. The pooled estimate of the frequency of 30-bp del-LMP1 and XhoI-loss in patients with NPC was 77% (95% confidence interval (CI): 72 to 82) and 82% (95% CI: 71 to 92), respectively. There was an association between 30-bp del-LMP1 and NPC susceptibility (OR = 2.86, 95% CI: 1.35 to 6.07, P = 0.00). Similarly, there was an association between XhoI-loss and NPC (OR = 8.5, 95% CI: 1.7 to 41, P = 0.00). However, when we analyze the co-existence of the 30-bp del-LMP1 and XhoI-loss in patients with NPC, there was no association (OR = 1.09, 95% CI: 0.06 to 18.79, P = 0.002).

Conclusions

Our results suggest an association between the 30-bp del-LMP1 and XhoI-loss with NPC susceptibility. However, our data should be interpreted with caution because the sample size was small, and there was heterogeneity between the studies. Thus, future studies are needed with adjusted estimates to simultaneously evaluate multiple factors involved in the development of NPC.

Systematic review registration

PROSPERO CRD42014013496.

Keywords

Epstein-Barr virus Nasopharyngeal carcinoma Meta-analysis Systematic review Latent membrane protein-1 XhoI-loss

Background

Nasopharyngeal carcinoma (NPC) is an aggressive tumor associated with Epstein-Barr virus (EBV) that initially affects the layer of epithelial cells in the nasopharynx and preferably arises in the Rosenmüller’s fossa [1,2]. NPC is also defined as a peculiar type of head and neck cancer due to its clinical status, etiology, pathology, epidemiology, and manner of response to treatment [3,4]. In view of these factors, EBV and NPC have very distinct epidemiological and clinical patterns, given that EBV is ubiquitous and causes a latent infection in 95% of the world population, with the majority of these infections being benign [5]. However, the worldwide incidence of NPC is considered rare, and affected individuals for many years had a poor prognosis that reflected in a reduced survival rate, but actually the survival of NPC patients is relatively high under the current treatment protocol and the introduction of intensity-modulated radiotherapy (IMRT) [6].

Although NPC endemicity is rare in most parts of the world [7], there is a striking geographic and ethnic distribution of cases characterized by existing areas of high endemicity (Southeast Asia), intermediate endemicity (Eastern Mediterranean and North Africa), and low endemicity (Americas). According to data provided by GLOBOCAN 2012 [8], in the same period in the world, the total number of NPC was 86,691 cases (age-standardized rate (ASR), 1.2/100,000)), while the number of deaths was 50,831 (ASR = 0.7/100,000). Among these cases, China was the country that contributed the most to these indices because it had the highest total number (33,198, ASR = 1.9/100,000) and deaths (20,404, ASR = 1.2/100,000) by NPC, followed by Indonesia (13,084 cases, ASR = 5.6/100,000 and 7,391 deaths with ASR = 3.3/100,000) and Vietnam (4,931 cases, ASR = 5.4/100,000 and 2,885 deaths with ASR = 3.3/100,000).

EBV infects the mucosal epithelium and B cells and consequently establishes a latent infection, and aberrant infection by EBV can to cause the appearance of tumors in these locations of replication [9]. Hence, infected cells may present physiological changes that result from the expression of latent genes, including mainly EB-encoded early RNAs (EBER), EBV nuclear antigens (EBNA1/2/3a,b,c) and latent membrane protein 1 or 2 (LMP1/2) [10].

The first protein from EBV to have its oncogenic properties empirically demonstrated was LMP1 [11], which is expressed on the cell surface, where it spontaneously aggregates to form a constitutively activated receptor, acting as a member of the tumor necrosis factor receptor (TNF-R) family and allowing LMP1 to exert an influence on the cell through interactions with different cellular molecules involved in an intracellular signaling cascade [12-15]. Consequently, a number of studies have shown the involvement of LMP1 in the pathogenesis of NPC [16,17], which involves the following factors: 1) an inhibition of apoptosis in the infected cells by the upregulation of Bcl-2 and A-20 genes [13,15,18]; 2) a modulation of the morphology and motility of epithelial cells [19]; 3) a downregulation of several suppressors for metastases [20]; 4) a promotion of angiogenesis [21]; and 5) an induction of the expression of proinflammatory cytokines, among other mechanisms [22,23]. LMP1 is an integral membrane protein that can be divided into three domains: 1) a short cytoplasmic N-terminal tail (amino acids 1 to 23); 2) six transmembrane alpha-helical of hydrophobic nature (amino acids 24 to 186); and 3) a long cytoplasmic C-terminal tail (amino acids 187 to 386), with this region having the highest LMP1 signaling activity. Therefore, the long cytoplasmic C-terminal tail has three distinct functional domains: C-terminal activation regions 1, 2, and 3 (CTAR1/2/3) [24,25].

The LMP1 gene has been shown to have polymorphisms, among which the occurrence of a 30-bp deletion is prominent, as compared with the prototype B95-8 LMP1, and occurs near the end of the cytoplasmic C-terminal tail and close to the functional domain CTAR2. This feature deletion has been studied, and it has been established that the 30-bp deletion results in an increased oncogenic activity of infected cells and results in a more aggressive phenotype of EBV-associated tumors [26,27]. In addition, another mutation observed in the LMP1 gene, albeit a point mutation, occurs at nucleotide position G169425T, resulting in the loss of a restriction site known as XhoI, which is present in the cytoplasmic N-terminal tail. Thus, the XhoI polymorphism has been commonly found in samples from patients with NPC but is absent in samples from healthy individuals [28,29]. However, in general, the results of the studies are ambiguous regarding the association of these variants in the EBV LMP1 gene with the risk of developing NPC. In this sense, this meta-analysis was performed to solve the problem of inadequate statistical power and of the controversial and ambiguous results.

Methods

We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) protocol, which provides rules and guidelines for systematic reviews and meta-analysis [30]. The PRISMA checklist is shown in Additional file 1. In addition, we prospectively recorded the study protocol in PROSPERO with the registration number CRD42014013496, available on the website http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42014013496#.VBg8HoctBdg.

The identification and eligibility of relevant studies

To address our study hypothesis, the following electronic databases were searched: PubMed, ScienceDirect, and SciELO. The selection period lasted until the beginning of September 2014, and the language of the studies to be selected should be expressed in English, Spanish, or Portuguese. Therefore, in these three electronic databases, the following keywords related to our research topic were added: Epstein-Barr virus OR EBV OR virus AND cancer OR tumor OR neoplasia OR nasopharyngeal carcinoma AND LMP1 30-bp deletion OR LMP1 variant OR BNLF1 AND XhoI polymorphism OR XhoI variants. We also adopted another strategy to search the data to reduce possible selection bias, which was the recovery of all references of ‘pre-selected’ studies to retrieve articles of interest available only in other electronic databases. Finally, the selection criteria were as follows: 1) cohort or case–control studies that analyzed the 30-bp deletion and/or XhoI-loss present in the EBV LMP1 gene of patients with NPC; and 2) studies that showed the variables of interest as previously stated were selected regardless of the place of origin of the search, age, and sex as well as the histological type of NPC presented by these individuals. The exclusion criteria included the following: 1) review studies; 2) analysis only of other cancers ‘non-NPC’; 3) duplicated previous publications; and 4) studies that did not disclose the variables of interest as the frequency of the 30-bp deletion or the XhoI polymorphism in the EBV LMP1 gene separately for patients with NPC.

Data extraction and quality assessment

The researchers independently reviewed and extracted information from the eligible studies according to the inclusion and exclusion criteria previously highlighted. Thus, the following data were extracted: the identification and design of the study, the year of publication, the number of subjects and controls who had NPC, the types of controls (healthy or pathological), the study site, the age and sex of the research subjects, the frequency of the outcomes of interest as the 30-bp deletion or XhoI-loss from the EBV LMP1 gene. To assess the methodological quality of observational studies was used Newcastle-Ottawa Scale (NOS) in which a study was judged on three categories: selection (four items, one star each), comparability (one item, up to two stars), and exposure/outcome (three items, one star each). A ‘star’ presents a ‘high-quality’ choice of individual study. The full score was 10 stars, and the high-quality study was defined as a study with ≥6 awarded stars [31].

Statistical analysis

The dichotomous data of the case–control studies were extracted and plotted in a 2 × 2 table to give the individual and combined odds ratios (OR). For the cohort studies, which have binary data, the variables were extracted to calculate an estimate of the frequency of the outcomes of interest, and a confidence interval (CI) of 95% was used whenever possible. The I2 index was used to evaluate the existence of heterogeneity between the studies; for cases where there were significant differences in terms of heterogeneity (I2 = 75% to 100%, P < 0.05) [32], the random-effect model was used for the individual and combined analysis of the data. We conducted a sensitivity analysis to test the effect of the individual influence of each study on the overall estimate, and a subgroup analysis was also performed to reduce the existence of heterogeneity. Furthermore, we evaluated the existence of publication bias by Begg’s funnel plot [33] and by Egger’s test [34]. The funnel plot for the case–control studies was developed from the standard error of the log (OR) for each analysis against the log (OR), whereas the funnel plot of the cohort studies was plotted from the standard error log (percent) against the log (percent). For all of the procedures of the meta-analysis, STATA IC/64 version 13.1 software (Stata Corporation, College Station, Texas, USA) was used.

Results

Initially, during our search for articles in the electronic databases, 1,280 reference studies were found (see Additional file 2). Subsequently, due to the selection of the inclusion and exclusion criteria, there was a refinement to 75 reference studies (see Additional file 3). Finally, 31 eligible studies remained, which constituted our database for conducting the present meta-analysis (Table 1) [29,35-64]. A total of 2,846 subjects were included in these studies, among which 1,855 and 991 individuals were placed in NPC and control groups, respectively. Regarding the sex of the individuals, there was a male predominance with a male/female ratio of 2.73 [39-42,46,49,53,54,57]. The age of the participants ranged from 8 to 87 years; however, the predominant age was approximately 50 years old [35,40,41,43,46,49,53-55]. Most of the participants came from Asia (approximately 71%) [29,35,36,38-41,43,46,47,49-51,53,55,57-59,61-64], followed by Europe (26%) [29,36,37,48,54,56,62,63], North Africa (19%) [42,44,52,56,60,62], and America (13%) [45,54,62,63]. Similarly, the samples were from at least 12 countries, consisting mainly of China, Taiwan, Russia, Malaysia, Tunisia, Indonesia, Thailand, Serbia, and Morocco. With regard to case–control studies, all had an NOS score of 7. In the cohort studies, 5 (42%) were of high quality (NOS score ≥6), with an average NOS score of 5 (see Additional file 4). Thus, the risk of bias in relation to study quality evaluated by NOS was considered low with a score ranging from 4 to 7.
Table 1

The characteristics of the studies included in the meta-analysis

Trial (year)

Location

Design

NPC 30-bp del-LMP1 EBV

XhoI-loss LMP1 EBV

Control group

   

Present

Not present

Type of sample

Present

Not present

Type of sample

N

Type of sample

Type of control

Senyuta et al. 2014 [35]

Russia

Case–control

4

18

Biopsy

   

15

PBMC

HD

Gurtsevitch et al. 2013 [36]

Russia

Case–control

3

18

Biopsy

   

13

PBMC

Non-NPC

Banko et al. 2012 [37]

Serbia

Case–control

1

15

Biopsy

   

30

PBMC

IM

Li et al. 2009 [38]

China

Case–control

43

7

Biopsy

   

56

PBMC

HD

See et al. 2008 [39]

Malaysia

Case–control

19

15

Biopsy

34

5

Biopsy

8

Biopsy

Non-NPC

Tang et al. 2008 [40]

China

Cohort

18

3

Biopsy

21

0

Biopsy

   

Tiwawech et al. 2008 [41]

Thailand

Case–control

44

31

PBL

   

44

PBMC

Non-NPC/HD

Ayadi et al. 2007 [42]

Tunisia

Cohort

41

6

Biopsy

0

47

Biopsy

   

Chang et al. 2006 [43]

Taiwan

Cohort

446

88

Biopsy

      

Dardari et al. 2006 [44]

Morocco

Case–control

51

10

Biopsy

   

17

PBMC

HD

Chabay et al. 2004 [45]

Argentina

Case–control

3

1

Biopsy

   

15

Biopsy/PBMC

Non-NPC

Min et al. 2004 [46]

China

Case–control

87

12

Biopsy

   

46

PBMC

HD

Nurhantari et al. 2003 [47]

Indonesia

Cohort

22

33

Biopsy

      

Plaza et al. 2003 [48]

Spain

Case–control

18

9

Biopsy

   

40

-

EBV-RC

Tan et al. 2003 [49]

Malaysia

Case–control

25

0

Biopsy

25

2

Biopsy

12

Biopsy

 

Zhang et al. 2002 [50]

China

Case–control

36

7

Biopsy

   

36

TW

HD

Hahn et al. 2001 [51]

Russia

Case–control

0

7

Biopsy

   

10

PBMC

HD

Henry et al. 2001 [52]

Tunisia

Cohort

3

3

Biopsy

0

6

Biopsy

   

Kuo et al. 2001 [53]

Taiwan

Cohort

2

0

Biopsy

      

D’Addario et al. 2000 [54]

Canada

Cohort

9

14

Biopsy

      

Cheung et al. 1998 [55]

China

Cohort

34

3

Biopsy

      

Grunewald et al. 1998 [56]

Multicenter

Case–control

46

18

Biopsy

   

45

PBMC

HD

Sung et al. 1998 [57]

China

Cohort

30

12

Biopsy

22

6

Biopsy

   

Cheung et al. 1996 [58]

China

Case–control

69

5

Biopsy

5

0

Biopsy

11

Biopsy

Non-NPC

Khanim et al. 1996 [29]

Multicenter

Case–control

24

4

Biopsy

19

9

Biopsy

14

Biopsy/PBMC

Non-NPC

Chang et al. 1995 [59]

Taiwan

Case–control

   

48

0

Biopsy

25

Biopsy/TW

HD

Bouzid et al. 1994 [60]

North Africa

Cohort

   

1

12

Biopsy

   

Jeng et al. 1994 [61]

Taiwan

Case–control

   

25

7

Biopsy

79

 

Non-NPC

Miller et al. 1994 [62]

Multicenter

Cohort

9

4

Biopsy

      

Abdel-Hamid et al. 1992 [63]

Multicenter

Case–control

   

33

18

Biopsy

19

-

Non-NPC

Hu et al. 1991 [64]

Multicenter

Cohort

   

38

18

Biopsy

   

Abbreviations: PBMC = peripheral blood mononuclear cell; PBL = peripheral blood lymphocyte; HD = healthy donors; IM = infective mononucleosis; TW = throat washing samples; NPC = nasopharyngeal carcinoma.

A meta-analysis to estimate the frequency of the 30-bp deletion and XhoI-loss (LMP1 EBV) in samples from NPC patients

The estimated frequencies of the EBV LMP1 variants in the samples from the NPC patients were determined and are shown in Figure 1. Thus, the estimated pooled frequency of 30-bp del-LMP1 was 77% (95% CI: 72 to 82, P = 0.00). For the control groups of the healthy controls and pathological samples, the estimated pooled frequency of 30-bp del-LMP1 was 46% (95% CI: 33 to 58, P = 0.00) and 39% (95% CI: 31 to 47, P = 0.49) (Additional file 5), respectively, that is, both of the control group frequencies were lower than those in the samples from the NPC patients.
Figure 1

Forest plot of the frequency of the occurrence of the two outcomes of interest in the patients with NPC. The confidence interval (CI) was 95%, and the diamond represents the pooled estimate. ID = identification of study.

For the XhoI-loss variable, the estimated pooled frequency was 82% (95% CI: 71 to 92, P = 0.00) in the NPC patients (see Figure 1). For the healthy and pathologic groups, the pooled rate was 62% (95% CI: 33 to 91, P = 0.002) and 76% (95% CI: 68 to 84, P = 0.3), respectively (Additional file 5).

The estimated pooled frequency was 79% (95% CI: 73 to 85, P = 0.00) for 30-bp del-LMP1 in the NPC patients found in Asia, which was the largest among the regions studied. The second highest frequency was observed in America, with a pooled frequency of 64% (95% CI: 35 to 93, P = 0.78). Finally, the third highest pooled frequency was 59% (95% CI: 45 to 73, P = 0.00), which was observed in Europe and North Africa. Similarly, the pooled frequency of XhoI-loss in individuals with NPC was higher for studies conducted in Asia (92%, 95% CI: 87 to 98, P = 0.00), followed by America (29%, 95% CI: 0 to 100) and by the regions from Europe and North Africa (9%, 95% CI: 0 to 44) (Additional file 6).

A meta-analysis of the association between the 30-bp del-LMP1 and XhoI-loss with NPC susceptibility

The OR, known as an association test, was calculated to assess the relationship between the LMP1 variants and NPC. Thus, there was a significant association between the 30-bp del-LMP1/XhoI-loss and NPC susceptibility (30-bp del-LMP1: OR = 2.86, 95% CI = 1.35 to 6.07, P = 0.00; XhoI-loss: OR = 8.5, 95% CI = 1.7 to 41, P = 0.00) (Figure 2). However, when we analyzed the association of the occurrence of the simultaneous outcome, that is, the co-existence of the 30-bp del-LMP1 and XhoI-loss with the susceptibility to NPC, there was not a significant association (OR = 1.09, 95% CI: 0.06 to 18.79, P = 0.002) (data not shown). However, there was significant heterogeneity, and due to this factor, the studies were analyzed in subgroups.
Figure 2

Forest plot of the OR for the 30-bp del-LMP1 and XhoI-loss in NPC. The diamond represents the pooled OR and its 95% confidence intervals (CIs). ID = identification of study.

The histological subsets of the NPC and LMP1 EBV variants

According to the World Health Organization (WHO), NPC can be classified into three types according to the degree of histopathological differentiation, which include type I (keratinizing squamous cells carcinoma), type IIa (non-keratinizing, previously classified as type II), and type IIb (undifferentiated carcinoma, previously classified as type III) [65]. Therefore, when the selected studies reported this information, they were divided according to the histopathological classification to assess the association between the types of NPC and the EBV LMP1 variants. Thus, a significant association was found between the occurrence of 30-bp del-LMP1 with type III NPC (OR = 2.6, 95% CI: 1.12 to 6.03, P = 0.006) and also with type I/II NPC (OR = 2.65, 95% CI: 1.45 to 4.85, P = 0.7). Similarly, there was a significant association between type III NPC and XhoI-loss (OR = 65, 95% CI: 1.8 to 2,369, P = 0.1); likewise there was an association for types I/II NPC and XhoI-loss (OR = 13.67, 95% CI: 3.12 to 60, P = 0.3) (Additional file 7).

The association between the EBV LMP1 variants and the susceptibility to NPC by study region

A significant association between 30-bp del-LMP1 and the susceptibility to NPC was found in the studies conducted in Asia (OR = 3.47, 95% CI: 1.36 to 8.86, P = 0.00), while for the studies conducted in Europe and North Africa, there was no association (OR = 1.01, 95% CI: 0.3 to 3.4, P = 0.00) (Figure 3A). Similarly, there was a higher association between XhoI-loss and NPC susceptibility for studies conducted in Asia (OR = 12.35, 95% CI: 3.98 to 38, P = 0.27). For the studies conducted in Europe and North Africa, there was no association between XhoI-loss and NPC susceptibility because the pooled OR was 0.12 (95% CI: 0.01 to 1.17, P = 0.5) (Figure 3B).
Figure 3

Forest plot of the odds ratio (OR) in relation to the origin from the studies for the outcome of the 30-bp del-LMP1 (A) and XhoI-loss (B) in patients with NPC. CI = confidence interval; ID = identification of study.

Sensitivity analysis and publication bias

The studies that presented results considered discordant were temporarily removed to assess their individual influences on the pooled ORs. The individual removal did not significantly affect the pooled OR. However, due to the large variation of the ORs between 30-bp del-LMP1 and the susceptibility to NPC found in the studies of Li et al. [38] and Tan et al. [49], the ORs were removed, and the pooled OR was reduced by 31%, reaching 2.86 (95% CI: 1.35 to 6.07) to 1.96 (95% CI: 1.05 to 3.66, P = 0.001). Similarly for XhoI-loss, the See et al. [39] and Tan et al. [49] studies exhibited an OR very different from the other studies, and when both were removed, the pooled OR was reduced by 8.5 and equaled 3.69 (95% CI: 0.75 to 18, P = 0.005). However, removing these studies did not reduce the significant heterogeneity found. Therefore, the reduction of heterogeneity observed in the studies that analyzed 30-bp del-LMP1 occurred when the following studies were removed: Senyuta et al. [35], Gurtsevitch et al. [36], Banko et al. [37], Li et al. [38], and Hahn et al. [51]. In this case, the heterogeneity was reduced to 48% (P = 0.036) with an OR of 3.51 (95% CI: 2 to 6) (data not shown).

For the studies that analyzed XhoI-loss, only the study conducted by Khanim et al. [29] was found to cause heterogeneity, and when it was removed, the heterogeneity decreased to 19% (P = 0.28) with a pooled OR of 16.83 (95% CI: 6 to 43).

For the analysis of the publication bias, a funnel plot was used, and because it was symmetrical, it indicated that the existence of a selection bias was unlikely (Additional file 8). Additionally, by Egger’s test, there was also no sign of the occurrence of a selection bias for the studies included in the estimate of the OR and for the studies that analyzed the outcome of 30-bp del-LMP1 (coefficient −1.22, 95% CI: −4 to 1.64, P value 0.36) or XhoI-loss (coefficient −8.2, 95% CI: −248 to 231, P value 0.7) in the biopsies from the NPC patients. Additionally, regarding the calculation of the frequency, there was no sign of publication bias by the funnel plot and by Egger’s test (30-bp del-LMP1, coefficient −0.9, 95% CI: −2 to 0.2, P value 0.1; XhoI, coefficient 0.2, 95% CI: −2.8 to 3.2, P value 0.9).

Discussion

This meta-analysis provided evidence that both the 30-bp deletion and XhoI-loss (EBV LMP1 gene) were more frequently found in the samples from patients with NPC than in the control groups. In this case, 30-bp del-LMP1 was 1.5 times higher in the NPC patients than in the control group. While the outcome of XhoI-loss was only 1.15 times higher in the NPC patients than in the control group, the simultaneous occurrence of the outcomes of interest (the co-existence of the 30-bp del-LMP1 and XhoI-loss), unlike our previous data, showed no association (OR = 1.9, 95% CI: 0.06 to 18.79), although this result has been found by a few studies. This result shows that LMP1 variants occur with a considerable frequency in healthy subjects; therefore, there are many other non-viral factors involved in the etiopathogenesis of NPC. Thus, it is known that the development of NPC is multifactorial, involving the existence of a genetic predisposition of the individual, along with environmental factors [66]. However, one of the factors that has been most often correlated with the risk of NPC is the viral factor.

Because the etiology of NPC is complex, other meta-analyses have emerged to analyze the involvement of various factors in the susceptibility to NPC. In this sense, Xue et al. [67] conducted a meta-analysis of cohort and case–control studies to establish the relationship between smoking and the risk of NPC. This analysis showed that individuals who smoked always had a 60% greater probability of risk for NPC compared to that of individuals who have never smoked. Regarding genetic predisposition, studies have found an association between glutathione S-transferase M1 (GSTM1) and glutathione S-transferase T1 (GSTT1) with an increased risk for the development of NPC [67,68]. Also, the role of human leukocyte antigen (HLA) in the emergence of NPC has been examined, and some specific haplotypes and/or alleles from the HLA region have been associated with NPC [69-71]. For this reason, studies have found a high prevalence of HLA allele patterns found in endemic NPC regions, for example, HLA-A2 and HLA-Bw46 [72,73], which were associated with an increased risk for the development of NPC. These results have shown that many genes may contribute to an increased susceptibility to NPC, and some interesting studies show that there is a pattern of distribution of the HLA haplotypes and/or alleles that vary in different geographical areas characterized by differences in the prevalence of NPC [72-75].

LMP1 is considered an oncogenic product from EBV, and although its expression has been positively correlated with metastasis in NPC [76], its etiopathogenesis remains poorly understood. In this context, authors have postulated that variants of LMP1 exist with greater tumorigenic potential, such as the specific 30-bp deletion at the C-terminal region and the loss of the restriction site at the N-terminus (XhoI), which were our target outcomes of interest. Consequently, our meta-analysis has found that there was a positive association, but we postulated that at this moment, this outcome alone does not explain the risk of the emergence and development of NPC because these LMP1 variants were also found with a considerable frequency in the control groups. Similarly, these LMP1 variants were found in other cancers, such as Burkitt’s lymphoma [77], gastric carcinoma [78], and Hodgkin’s lymphoma [79,80], and also in the Japanese population [81]. With this background, the two LMP1 variants cannot be considered specific markers of NPC but could be considered the predominant variants in this type of cancer.

One factor that always draws attention in NPC is its remarkable geographical distribution because, while NPC is rare in most of the world, for the Southeast Asian region, especially in the South China region, this type of cancer is endemic. For example, the incidence of NPC in some provinces of Southern China is up to 30 times higher than in the rest of the world [82]. Thus, the question inevitably arises: what are the factors that explain the higher incidence of NPC in these endemic regions? Initially, the answer was related to an increased susceptibility of the people of these regions with the 30-bp del-LMP1 variant, as this is a variant commonly found in NPC biopsies. However, Zhang et al. [50] found similar levels of this LMP1 polymorphism among samples from endemic and non-endemic regions in South and North China, respectively. Therefore, the LMP1 variant failed to explain the high incidence of NPC in China, showing that there are other complex factors. Although these regions are composed of a very similar ethnic group, most likely, there are some genetic differences among this population. Accordingly, Wang et al. [83] found a higher frequency of HLA-A (*)30 in healthy individuals from the North China region, which has been associated with NPC resistance. Additionally, Ren et al. [84] found that the risk of developing NPC increases with a family history of the disease, meaning that individuals in South China who have a greater family history and incidence of NPC consequently have a greater susceptibility to NPC.

As previously mentioned, although EBV is associated with NPC, it most likely is not the only factor that would justify the high incidence of NPC in some parts of the world. A set of factors could contribute to the emergence of NPC, such as the type of diet, especially considering that multiple dietary factors, such as a high consumption of salted fish and eggs have been associated with the risk of NPC [85]. In addition, several authors have consistently found an associated risk between NPC and individuals who often feed on salt-preserved fish. These data were obtained from regions endemic for NPC, where this type of food is traditional for the people who live in these places [86,87].

This is the first meta-analysis that evaluated an association between the 30-bp deletion and XhoI-loss (EBV LMP1 gene) on the risk of NPC. Our results suggest an association between the outcomes of interest. However, we recognize that there were some limitations in our study. First, there was significant heterogeneity in the results; thus, a sensitivity analysis and subgroups showed that the types of controls and histologic types from NPC caused heterogeneity, but we did cannot determine if other variables such as the sample size or the origin of the studies caused the heterogeneity. Second, the loss of the original data from the reviewed studies limited our evaluation of other potential interactions, such as survival analysis and the stage of NPC associated with the LMP1 variants. Third, the number of studies included in the analysis was high, but the sample sizes included in the studies were modest. This factor may reduce the statistical power of the association between the outcome of interest and the risk of cancer. Fourth, articles in the Chinese language were not included; consequently, there is a possibility of a selection bias, even with the funnel plot and Egger’s test indicating no significant publication bias. Finally, our results of the ORs are based on unadjusted estimates, which may suffer from a confounding bias; therefore, a more precise analysis is required and must be conducted and adjusted for other factors jointly, such as cancer stage, age, sex, and genetic and environmental factors involved.

Conclusions

Our results suggest an association between the 30-bp del-LMP1 and XhoI-loss with NPC susceptibility. However, our data should be interpreted with caution because the sample size was small, and there was heterogeneity between the studies. For sensitivity analysis, individual removal did not significantly affect heterogeneity and the pooled ORs. In summary, further studies with a larger number of individuals will be required to measure the overall joint association of the various factors that might be involved in the triggering of NPC.

Abbreviations

CTAR: 

C-terminal activation regions

EBV: 

Epstein-Barr virus

GSTM1: 

Glutathione S-transferase M1

GSTT1: 

Glutathione S-transferase T1

HLA: 

Human leukocyte antigen

LMP: 

Latent membrane protein

NOS: 

Newcastle-Ottawa Scale

NPC: 

Nasopharyngeal carcinoma

PRISMA: 

Preferred Reporting Items for Systematic Reviews and Meta-Analyses

Declarations

Acknowledgements

This study was supported by Fundação de Amparo à Pesquisa do Estado de Goiás (FAPEG; N° 10/13-Apoio Programas de Pós-Graduação Stricto Sensu). The funders had no role in the study; the collection, analysis, and interpretation of data; or assembly and decision to submit this manuscript.

Authors’ Affiliations

(1)
Post-Graduation Program in Applied Health Sciences, Federal University of Goiás
(2)
Virology Laboratory, Federal University of Goiás

References

  1. Pathmanathan R, Prasad U, Sadler R, Flynn K, Raab-Traub N. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med. 1995;333:693–8.View ArticlePubMedGoogle Scholar
  2. Sham JS, Wei WI, Zong YS, Choy D, Guo YQ, Luo Y, et al. Detection of subclinical nasopharyngeal carcinoma by fibreoptic endoscopy and multiple biopsy. Lancet. 1990;335:371–4.View ArticlePubMedGoogle Scholar
  3. Fandi A, Altun M, Azli N, Armand JP, Cvitkovic E. Nasopharyngeal cancer: epidemiology, staging, and treatment. Semin Oncol. 1994;21:382–97.PubMedGoogle Scholar
  4. Agulnik M, Epstein JB. Nasopharyngeal carcinoma: current management, future directions and dental implications. Oral Oncol. 2008;44:617–27.View ArticlePubMedGoogle Scholar
  5. Rickinson AB, Kieff E. Epstein-Barr virus. In: Knipe DM, Howley PM, editors. Field’s Virology. 4th ed. Philadelphia, Pa, USA: Lippincott Williams & Wilkins; 2001. p. 2575–627.Google Scholar
  6. Leung SW, Lee TF. Treatment of nasopharyngeal carcinoma by tomotherapy: five-year experience. Radiation Oncol. 2013;8:107.View ArticleGoogle Scholar
  7. Wei WI, Sham JST. Nasopharyngeal carcinoma. Lancet. 2005;365:2041–54.View ArticlePubMedGoogle Scholar
  8. GLOBOCAN. Estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/summary_table_pop_sel.aspx. Accessed 14 Jan 2015.
  9. Young LS, Rickinson AB. Epstein-Barr virus: 40 years. Nat Rev Cancer. 2004;4:757–68.View ArticlePubMedGoogle Scholar
  10. Izumi KM. Identification of EBV transforming genes by recombinant EBV technology. Semin Cancer Biol. 2001;11:407–14.View ArticlePubMedGoogle Scholar
  11. Wang D, Liebowitz D, Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell. 1985;43:831–40.View ArticlePubMedGoogle Scholar
  12. Kilger E, Kieser A, Baumann M, Hammerschmidt W. Epstein-Barr virus–mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J. 1998;17:1700–9.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Tsao SW, Tramoutanis G, Dawson CW, Lo AK, Huang DP. The significance of LMP1 expression in nasopharyngeal carcinoma. Semin Cancer Biol. 2002;12:473–87.View ArticlePubMedGoogle Scholar
  14. Morris MA, Dawson CW, Young LS. Role of the Epstein–Barr virus-encoded latent membrane protein-1, LMP1, in the pathogenesis of nasopharyngeal carcinoma. Future Oncol. 2009;5:811–25.View ArticlePubMedGoogle Scholar
  15. Li HP, Chang YS. Epstein-Barr virus latent membrane protein 1: structure and functions. J Biomed Sci. 2003;10:490–504.View ArticlePubMedGoogle Scholar
  16. Dawson CW, Port RJ, Young LS. The role of the EBV-encoded latent membrane proteins LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma (NPC). Semin Cancer Biol. 2012;22:144–53.View ArticlePubMedGoogle Scholar
  17. Raab-Traub N. Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol. 2002;12:431–41.View ArticlePubMedGoogle Scholar
  18. Zheng H, Li LL, Hu DS, Deng XY, Cao Y. Role of Epstein-Barr virus encoded latent membrane protein 1 in the carcinogenesis of nasopharyngeal carcinoma. Cell Mol Immunol. 2007;4:185–96.PubMedGoogle Scholar
  19. Wakisaka N, Pagano JS. Epstein-Barr virus induces invasion and metastasis factors. Anticancer Res. 2003;23:2133–8.PubMedGoogle Scholar
  20. Shen ZH, Chen XY, Chen J. Impact of up-regulating Ezrin expression by Epstein-Barr virus latent membrane protein 1 on metastasis ability of nasopharyngeal carcinoma cells. Ai Zheng. 2008;27:165–9.PubMedGoogle Scholar
  21. Yoshizaki T, Horikawa T, Qing-Chun R, Wakisaka N, Takeshita H, Sheen TS, et al. Induction of interleukin-8 by Epstein-Barr virus latent membrane protein-1 and its correlation to angiogenesis in nasopharyngeal carcinoma. Clin Cancer Res. 2001;7:1946–51.PubMedGoogle Scholar
  22. Busson P, Braham K, Ganem G, Thomas F, Grausz D, Lipinski M, et al. Epstein-Barr virus-containing epithelial cells from nasopharyngeal carcinoma produce interleukin-1. Proc Natl Acad Sci U S A. 1987;84:6262–6.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Huang YT, Sheen TS, Chen CL, Lu J, Chang Y, Chen JY, et al. Profile of cytokine expression in nasopharyngeal carcinomas: a distinct expression of interleukin 1 in tumor and CD4+ T cells. Cancer Res. 1999;59:1599–605.PubMedGoogle Scholar
  24. Coffin WF, Erickson KD, Hoedt-Miller M, Martin JM. The cytoplasmic amino-terminus of the latent membrane protein-1 of Epstein-Barr virus: relationship between transmembrane orientation and effector functions of the carboxy-terminus and transmembrane domain. Oncogene. 2001;20:5313–30.View ArticlePubMedGoogle Scholar
  25. Gires O, Zimber-Strobl U, Gonnella R, Ueffing M, Marschall G, Zeidler R, et al. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J. 1997;16:6131–40.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Li SN, Chang YS, Liu ST. Effect of a 10-amino acid deletion on the oncogenic activity of latent membrane protein 1 of Epstein-Barr virus. Oncogene. 1996;12:2129–35.PubMedGoogle Scholar
  27. Knecht H, Bachmann E, Brousset P, Sandvej K, Nadal D, Bachmann F, et al. Deletions within the LMP1 oncogene of Epstein-Barr virus are clustered in Hodgkin’s disease and identical to those observed in nasopharyngeal carcinoma. Blood. 1993;82:2937–42.PubMedGoogle Scholar
  28. Chen ML, Tsai CN, Liang CL, Shu CH, Huang CR, Sulitzeanu D, et al. Cloning and characterization of the latent membrane protein (LMP) of a specific Epstein-Barr virus variant derived from the nasopharyngeal carcinoma in the Taiwanese population. Oncogene. 1992;7:2131–40.PubMedGoogle Scholar
  29. Khanim F, Yao QY, Niedobitek G, Sihota S, Rickinson AB, Young LS. Analysis of Epstein-Barr virus gene polymorphisms in normal donors and virus-associated tumors from different geographical locations. Blood. 1996;88:3491–501.PubMedGoogle Scholar
  30. Moher D, Liberati A, Tetzlaff J, Altman DG, The PG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009;6, e1000097.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et. al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Health Research Institute. Available: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
  32. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.View ArticlePubMedGoogle Scholar
  33. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.View ArticlePubMedGoogle Scholar
  34. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.View ArticlePubMedPubMed CentralGoogle Scholar
  35. Senyuta N, Yakovleva L, Goncharova E, Scherback L, Diduk S, Smirnova K, et al. Epstein–Barr virus latent membrane protein 1 polymorphism in nasopharyngeal carcinoma and other oral cavity tumors in Russia. J Med Virol. 2014;86:290–300.View ArticlePubMedGoogle Scholar
  36. Gurtsevitch VE, Yakovleva LS, Shcherbak LN, Goncharova EV, Smirnova KV, Diduk SV, et al. Sequence variants of LMP1 oncogene in patients with oral cavity tumors associated and not associated with Epstein-Barr virus. Mol Biol. 2013;47:863–70.View ArticleGoogle Scholar
  37. Banko A, Lazarevic I, Cupic M, Stevanovic G, Boricic I, Jovanovic T. Carboxy-terminal sequence variation of LMP1 gene in Epstein–Barr-virus-associated mononucleosis and tumors from Serbian patients. J Med Virol. 2012;84:632–42.View ArticlePubMedGoogle Scholar
  38. Li DJ, Bei JX, Mai SJ, Xu JF, Chen LZ, Zhang RH, et al. The dominance of China 1 in the spectrum of Epstein-Barr virus strains from Cantonese patients with nasopharyngeal carcinoma. J Med Virol. 2009;81:1253–60.View ArticlePubMedGoogle Scholar
  39. See HS, Yap YY, Yip WK, Seow HF. Epstein-Barr virus latent membrane protein-1 (LMP-1) 30-bp deletion and Xho I-loss is associated with type III nasopharyngeal carcinoma in Malaysia. World J Surg Oncol. 2008;6:1–10.View ArticleGoogle Scholar
  40. Tang YL, Lu JH, Cao L, Wu MH, Peng SP, Zhou HD, et al. Genetic variations of EBV-LMP1 from nasopharyngeal carcinoma biopsies: potential loss of T cell epitopes. Braz J Med Biol Res. 2008;41:110–6.View ArticlePubMedGoogle Scholar
  41. Tiwawech D, Srivatanakul P, Karalak A, Ishida T. Association between EBNA2 and LMP1 subtypes of Epstein-Barr virus and nasopharyngeal carcinoma in Thais. J Clin Virol. 2008;42:1–6.View ArticlePubMedGoogle Scholar
  42. Ayadi W, Feki L, Khabir A, Boudawara T, Ghorbel A, Charfeddine I, et al. Polymorphism analysis of Epstein-Barr virus isolates of nasopharyngeal carcinoma biopsies from Tunisian patients. Virus Gene. 2007;34:137–45.View ArticleGoogle Scholar
  43. Chang KP, Hao SP, Lin SY, Ueng SH, Pai PC, Tseng CK, et al. The 30-bp deletion of Epstein-Barr virus latent membrane protein-1 gene has no effect in nasopharyngeal carcinoma. Laryngoscope. 2006;116:541–6.View ArticlePubMedGoogle Scholar
  44. Dardari R, Khyatti M, Cordeiro P, Odda M, ElGueddari B, Hassar M, et al. High frequency of latent membrane protein-1 30-bp deletion variant with specific single mutations in Epstein-Barr virus-associated nasopharyngeal carcinoma in Moroccan patients. Int J Cancer. 2006;118:1977–83.View ArticlePubMedGoogle Scholar
  45. Chabay P, De Matteo E, Merediz A, Preciado MV. High frequency of Epstein Barr virus latent membrane protein-1 30 bp deletion in a series of pediatric malignancies in Argentina. Arch Virol. 2004;149:1515–26.View ArticlePubMedGoogle Scholar
  46. Min Z, Young-sheng Z, Jie-hua HE, Su-xia L, Bi-ling Z, Ying-jie Y. Comparison of Epstein-Barr virus infection and 30 bp-deleted LMP1 gene among four histological types of nasopharyngeal carcinoma. Chin Med J. 2004;117:608–11.Google Scholar
  47. Nurhantari Y, Emoto N, Rahayu P, Matsuo M. Nasopharyngeal carcinoma in Indonesia has a low prevalence of the 30-base pair deletion of Epstein-Barr virus latent membrane protein 1. Southeast Asian J Trop Med Public Health. 2003;34:98–105.PubMedGoogle Scholar
  48. Plaza G, Santón A, Vidal AM, Bellas C. Latent membrane protein-1 oncogene deletions in nasopharyngeal carcinoma in Caucasian patients. Acta Otolaryngol. 2003;123:664–8.View ArticlePubMedGoogle Scholar
  49. Tan EL, Peh SC, Sam CK. Analyses of Epstein-Barr virus latent membrane protein-1 in malaysian nasopharyngeal carcinoma: high prevalence of 30-bp deletion, Xho1 polymorphism and evidence of dual infections. J Med Virol. 2003;69:251–7.View ArticlePubMedGoogle Scholar
  50. Zhang XS, Song KH, Mai HQ, Jia WH, Feng BJ, Xia JC, et al. The 30-bp deletion variant: a polymorphism of latent membrane protein 1 prevalent in endemic and non-endemic areas of nasopharyngeal carcinomas in China. Cancer let. 2002;176:65–73.View ArticleGoogle Scholar
  51. Hahn P, Novikova E, Scherback L, Janik C, Pavlish O, Arkhipov V, et al. The LMP1 gene isolated from Russian nasopharyngeal carcinoma has no 30-bp deletion. Int J Cancer. 2001;91:815–21.View ArticlePubMedGoogle Scholar
  52. Henry S, Sacaze C, Berrajah L, Karray H, Drira M, Hammami A, et al. In nasopharyngeal carcinoma-bearing patients, tumors and lymphocytes are infected by different Epstein-Barr virus strains. Int J Cancer. 2001;91:698–704.View ArticlePubMedGoogle Scholar
  53. T-t K, Tsang NM. Salivary gland type nasopharyngeal carcinoma: a histologic, immunohistochemical, and Epstein-Barr virus study of 15 cases including a psammomatous mucoepidermoid carcinoma. Am J Surg Pathol. 2001;25:80–6.View ArticleGoogle Scholar
  54. D’Addario M, Chauvin P. Ethnic differences in the expression of Epstein-Barr virus latent membrane protein-1 mutations in nasopharyngeal carcinoma. Mutat Res. 2000;457:69–78.View ArticlePubMedGoogle Scholar
  55. Cheung ST, Leung SF, Lo KW, Chiu KW, Tam JSL, Fok TF, et al. Specific latent membrane protein 1 gene sequences in type 1 and type 2 Epstein-Barr virus from nasopharyngeal carcinoma in Hong Kong. Int J Cancer. 1998;76:399–406.View ArticlePubMedGoogle Scholar
  56. Grunewald V, Bonnet M, Boutin S, Yip T, Louzir H, Levrero M, et al. Amino-acid change in the Epstein-Barr virus zebra protein in undifferentiated nasopharyngeal carcinomas from Europe and North Africa. Int J Cancer. 1998;75:497–503.View ArticlePubMedGoogle Scholar
  57. Sung NS, Edwards RH, Seillier-Moiseiwitsch F, Perkins AG, Zeng Y, Raab-Traub N. Epstein-Barr virus strain variation in nasopharyngeal carcinoma from the endemic and non-endemic regions of China. Int J Cancer. 1998;76:207–15.View ArticlePubMedGoogle Scholar
  58. Cheung ST, Lo KW, Leung SF, Chan WY, Choi PH, Johnson PJ, et al. Prevalence of LMPl deletion variant of Epstein-Barr Virus in nasopharyngeal carcinoma and gastric tumors in Hong Kong. Int J Cancer. 1996;66:711–2.View ArticlePubMedGoogle Scholar
  59. Chang YS, Su IJ, Chung PJ, Shu CH, Ng CK, Wu SJ, et al. Detection of an Epstein-Barr virus variant in T-cell-lymphoma tissues identical to the distinct strain observed in nasopharyngeal carcinoma in the Taiwanese population. Int J Cancer. 1995;62:673–7.View ArticlePubMedGoogle Scholar
  60. Bouzid M, Djennaoui D, Dubreuil J, Bouguermouh A, Ellouz D, Abdelwahab J, et al. Epstein-Barr virus genotypes in NPC biopsies from North Africa. Int J Cancer. 1994;56:468–73.View ArticlePubMedGoogle Scholar
  61. Jeng KCG, Hsu CY, Liu MT, Chung TT, Liu ST. Prevalence of Taiwan variant of Epstein-Barr virus in throat washings from patients with head and neck tumors in Taiwan. J Clin Microbiol. 1994;32:28–31.PubMedPubMed CentralGoogle Scholar
  62. Miller WE, Edwards RH, Walling DM, Raab-Traub N. Sequence variation in the Epstein-Barr virus latent membrane protein 1. J General Virol. 1994;75:2729–40.View ArticleGoogle Scholar
  63. Abdel-Hamid M, Chen JJ, Constantine N, Massoud M, Raab-Traub N. EBV strain variation: geographical distribution and relation to disease state. Virology. 1992;190:168–75.View ArticlePubMedGoogle Scholar
  64. Hu LF, Zabarovsky ER, Chen F, Cao SL, Ernberg I, Klein G, et al. Isolation and sequencing of the Epstein-Barr virus BNLF-1 gene (LMP1) from a Chinese nasopharyngeal carcinoma. J General Virol. 1991;72:2399–409.View ArticleGoogle Scholar
  65. Shanmugaratnam K, Path FRC, Sobin LH. The World Health Organization histological classification of tumours of the upper respiratory tract and ear. A commentary on the second edition. Cancer. 1993;71:2689–97.View ArticlePubMedGoogle Scholar
  66. Laantri N, Corbex M, Dardari R, Benider A, Gueddari BE, Khyatti M. Environmental, genetic and viral risk factors of nasopharyngeal carcinoma in North Africa. BMC Proceeding. 2011;5 Suppl 1:30.View ArticleGoogle Scholar
  67. Xue WQ, Qin HD, Ruan HL, Shugart YY, Jia WH. Quantitative association of tobacco smoking with the risk of nasopharyngeal carcinoma: a comprehensive meta-analysis of studies conducted between 1979 and 2011. Am J Epidemiol. 2013;178:325–38.View ArticlePubMedPubMed CentralGoogle Scholar
  68. Murthy AK, Kumar V, Suresh KP. Meta-analysis of GSTM1 and GSTT1 polymorphisms and risk of nasopharyngeal cancer. Asian Pacific J Cancer Prev. 2013;14:1697–701.View ArticleGoogle Scholar
  69. Chin YM, Mushiroda T, Takahashi A, Kubo M, Krishnan G, Yap LF, et al. HLA-A SNPs and amino acid variants are associated with nasopharyngeal carcinoma in Malaysian Chinese. Int J Cancer. 2014. doi:10.1002/ijc.29035.
  70. Li X, Ghandri N, Piancatelli D, Adams S, Chen D, Robbins FM, et al. Association between HLA Class I alleles and the prevalence of nasopharyngeal carcinoma (NPC) among Tunisians. J Transl Med. 2007;5:22.View ArticlePubMedPubMed CentralGoogle Scholar
  71. Burt RD, Vaughan TL, McKnight B, Davis S, Beckmann AM, Smith AG, et al. Associations between human leukocyte type and nasopharyngeal carcinoma in Caucasian in the Unites States. Cancer Epidemiol Biomarkers Prev. 1996;5:879–87.PubMedGoogle Scholar
  72. Li X, Fasano R, Wang E, Yao KT, Marincola FM. HLA associations with nasopharyngeal carcinoma. Curr Mol Med. 2009;9:751–65.View ArticlePubMedPubMed CentralGoogle Scholar
  73. Tang M, Zeng Y, Poisson A, Marti D, Guan L, Zheng Y, et al. Haplotype-dependent HLA susceptibility to nasopharyngeal carcinoma in a Southern Chinese population. Genes Immun. 2010;11:334–42.View ArticlePubMedPubMed CentralGoogle Scholar
  74. Feng BJ, Huang W, Shugart YY, Lee MK, Zhang F, Xia JC, et al. Genome-wide scan for familial nasopharyngeal reveals evidence of linkage to chromosome 4. Nat Genet. 2002;31:395–9.PubMedGoogle Scholar
  75. Simons MJ, Wee GB, Chan SH, Shanmugaratnam K, Day NE, De-Thé G. Immunogenetic aspects of nasopharyngeal carcinoma (NPC) III. HL-a type as a genetic marker of NPC predisposition to test the hypothesis that Epstein-Barr virus is an etiological factor in NPC. IARC Sci Publ. 1975;11:249–58.PubMedGoogle Scholar
  76. Zhao Y, Wang Y, Zeng S, Hu X. LMP1 expression is positively associated with metastasis of nasopharyngeal carcinoma: evidence from a meta-analysis. J Clin Pathol. 2012;65:41–5.View ArticlePubMedGoogle Scholar
  77. Chen WG, Chen YY, Bacchi MM, Bachi CE, Alvarenga M, Weiss LM. Genotyping of Epstein-Barr virus in Brazilian Burkitt’s lymphoma and reactive lymphoid tissue: type A with high prevalence of deletion within the latent membrane protein gene. Am J Pathol. 1996;148:17–23.PubMedPubMed CentralGoogle Scholar
  78. Mori S, Itoh T, Tokunaga M, Eizuru Y. Deletions and single-base mutations within the carboxy-terminal region of the latent membrane protein 1 oncogene in Epstein-Barr virus-related gastric cancers of southern Japan. J Med Virol. 1999;57:152–8.View ArticlePubMedGoogle Scholar
  79. Dirnhofer S, Angeles-Angeles A, Ortiz-Hidalgo C, Reyes E, Gredler E, Krugmann J, et al. High prevalence of a 30-base pair deletion in the Epstein-Barr virus (EBV) latent membrane protein 1 gene and of strain type B EBV in Mexican classical Hodgkin’s disease and reactive lymphoid tissue. Hum Pathol. 1999;30:781–7.View ArticlePubMedGoogle Scholar
  80. Essop MF, Engel M, Close P, Sinclair-Smith C, Pallesen G. Epstein-barr virus in Hodgkin’s disease: frequency of a 30-bp deletion in the latent membrane protein (LMP-1) oncogene in South African patients. Int J Cancer. 1999;20:449–51.View ArticleGoogle Scholar
  81. Itakura O, Yamada S, Narita M, Kikuta H. High prevalence of a 30-base pair deletion and single-base mutations within the carboxy terminal end of the LMP-1 oncogene of Epstein-Barr virus in the Japanese population. Oncogene. 1996;13:1549–53.PubMedGoogle Scholar
  82. Jia WH, Huang QH, Liao J, Ye W, Shugart YY, Liu Q, et al. Trends in incidence and mortality of nasopharyngeal carcinoma over a 20–25 year period (1978/1983–2002) in Sihui and Cangwu counties in southern China. BMC Cancer. 2006;6:178.View ArticlePubMedPubMed CentralGoogle Scholar
  83. Wang R, Hu Y, Yindom LM, Huang L, Wu R, Wang D, et al. Association analysis between HLA-A, −B, −C, −DRB1, and –DQB1 with nasopharyngeal carcinoma among a Han population in Northwestern China. Hum Immunol. 2014;75:197–202.View ArticlePubMedGoogle Scholar
  84. Ren ZF, Liu WS, Qin HD, Xu YF, Yu DD, Feng QS, et al. Effect of family history of cancers and environmental factors on risk of nasopharyngeal carcinoma in Guangdong China. Cancer Epidemiol. 2010;34:419–24.View ArticlePubMedGoogle Scholar
  85. Armstrong RW, Imrey PB, Lye MS, Armstrong MJ, Yu M, Sani S. Nasopharyngeal carcinoma in Malaysian Chinese: salted fish and other dietary exposures. Int J Cancer. 1998;77:228–35.View ArticlePubMedGoogle Scholar
  86. Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2006;15:1765–77.View ArticlePubMedGoogle Scholar
  87. Yuan JM, Wang XL, Xiang YB, Gao YT, Ross RK, Yu MC. Preserved foods in relation to risk of nasopharyngeal carcinoma in Shanghai. China Int J Cancer. 2000;85:358–63.View ArticlePubMedGoogle Scholar

Copyright

© da Costa et al.; licensee BioMed Central. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement